Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SHR-A1811 plus adebrelimab for early or locally advanced HR-negative/low, HER2-low breast cancer
CTR20243415Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, adebrelimab in breast cancer, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Sep 2024; status: active.
02
Drugs
trastuzumab rezetecanadebrelimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20243415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243415.